The Albany Gazette - Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21

NYSE - LSE

BCC	0.74%	74.7	$
RYCEF	1.14%	19.3	$
RBGPF	0%	65	$
NGG	-0.65%	75.33	$
CMSC	3.13%	20.16	$
RIO	-1.4%	92.87	$
BCE	-2.11%	19.92	$
VOD	1.4%	16.38	$
JRI	0%	10.77	$
GSK	-2.1%	47.18	$
RELX	0.93%	33.49	$
AZN	-2.39%	157.7	$
BP	1.15%	44.5	$
BTI	-2.27%	53.19	$
CMSD	2.61%	20.34	$

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21

BOULEVARD 08.05.2025

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21

HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that Kraig Higginson, Chief Executive Officer of Aspire, will be presenting at the upcoming Sidoti Virtual Investor Conference on May 21 at 2:30 PM Eastern. Investors and other interested individuals may access the virtual presentation here: https://sidoti.zoom.us/webinar/register/WN_q62DwzilROyKt-kOh_GJDQ

Text size:

One-on-One Meetings

Inspire will also host virtual one-on-ones with investors on Wednesday, May 21 and Thursday, May 22, 2025. To register for the presentation or one-on ones, visit https://sidoti.com/events.

A replay of the presentation will be available on the investor relations section of Inspire's website at https://ir.aspirebiolabs.com/events/

About Aspire Biopharma, Inc.

Headquartered in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology through a Novel Soluble Formulation which addresses emergencies, drug efficacy, dosage management, and response time. For more information, please visit www.aspirebiolabs.com.

Safe Harbor Statement

Certain statements made in this communication are "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as "estimate," "projects," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "would," "should," "future," "propose," "potential," "target," "goal," "objective," "outlook" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Aspire Biopharma Holdings, Inc.

Contact

TraDigital IR
Kevin McGrath
+1-646-418-7002
[email protected]

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

(J.Torres--TAG)